
Krsnaa Diagnostics Q1 FY25 Earnings Call Analysis
Revenue, margin, capex, fundraise and order book outlook from management commentary.
Management growth scorecard
Revenue
Category 3
Margin
Category 1
Fundraise
N/A
Order
Yes
Capex
Yes
3 of 4 growth signals are positive.
Full analysisRevenue guidance
Category 3- Krsnaa Diagnostics aims for a base revenue growth of 25% with an aspirational target of around 30% by FY25 end.
- Q1 FY25 revenue reached Rs.170 crores, showing a 22% YoY increase, indicating strong momentum.
- The company plans to expand retail operations over the next 6-12 months, which is expected to stabilize and add to margin and revenue growth.
- Punjab is on a continued growth trajectory with increasing month-on-month volumes.
- Projects like MRI and CT deployments in Maharashtra and other states are expected to increase volumes during FY25.
- Potential Rajasthan tender, if awarded, could add 300-400 crores in revenues with a 9-12 month ramp-up timeline.
- Overall growth is supported by both expansion in mature PPP centers and new centers coming online, with new centers expected to improve margins gradually.
- Retail foray targets to capture a large addressable market (~Rs. 40,000 crores) by leveraging existing diagnostic infrastructure without adding new franchises.
See what Krsnaa Diagnostics management said on margin guidance — free account, 30 seconds.
Fundraise plans
- There is no explicit mention of any current or planned new fundraising through debt or equity in the earnings call transcript.
- The company reported a gross debt of Rs.170 crores and cash & cash equivalents of Rs.240 crores as of June 30, 2024, maintaining a net debt-free position.
- For the Rajasthan project (a potential large opportunity), vendor financing commitments from OEM manufacturers exist, enabling deployment of equipment with limited cash outflow and no immediate large capital expenditure required from company reserves.
- The company plans CAPEX of Rs.170 crores for FY25, with Rs.22 crores already spent in Q1, funded through internal means and vendor financing.
- No indications of equity fundraising or new debt issuance were disclosed during the call.
See what Krsnaa Diagnostics management said on order book — free account, 30 seconds.
Capex plans
Yes- Planned CAPEX for FY25 is Rs.170 crores, with Rs.22 crores already spent in Q1.
- CAPEX is mainly focused on radiology projects in Maharashtra and Madhya Pradesh, including deployment of CT scans and MRIs.
- Maharashtra plans include operationalizing 21 CT centers with another 18 soon, plus installing seven more CT machines and five MRIs by year-end.
- Madhya Pradesh MRI project involves installing five MRIs; two centers expected operational by year-end.
- Vendor financing arrangements are in place for Rajasthan tender equipment, enabling asset deployment with minimal immediate cash outgo.
- Retail expansion involves setting up 40 leased labs leveraging existing PPP infrastructure to grow consumer and B2B revenues.
- The company is targeting to increase presence through the retail franchise by digital and offline channels without establishing new franchises but leveraging existing networks.
Track Krsnaa Diagnostics — get its next earnings analysis in your feed
How does Krsnaa Diagnostics rank vs peers in Healthcare Services?
Pro featureHow does Krsnaa Diagnostics rank in Healthcare Services?
Compare Krsnaa Diagnostics against every Healthcare Services company (Q1 FY25) on revenue, margins and earnings-call signals.
Continue your research
What Krsnaa Diagnostics's management said in earlier quarters
Others in Healthcare Services this season
- Chandan Healthca (Q2 FY27)
Q2 FY27 operating income: ₹57.94 Cr, up 45.04% YoY from ₹39.95 Cr (Page 8) . Key investor presentation takeaways from Chandan Healthcare Ltd's Q2 FY27 investor
- Invicta Diagnostic (Q2 FY27)
Revenue from operations for the half year ended September 30, 2026: ₹379.11 lakhs (Page 4). Key results statement takeaways from Invicta Diagnostic Ltd's Q2 FY2
- Unihealth Hosp (Q2 FY27)
1,270 million with a year-on-year (YoY) growth of 6.3% . Key results statement takeaways from Unihealth Hospitals Ltd's Q2 FY27 results statement — and how it r
- Sangani Hospital (Q2 FY27)
1008.56 lakhs (~11.8% increase). Key results statement takeaways from Sangani Hospitals Ltd's Q2 FY27 results statement — and how it ranks against sector peers.